Completed PHASE3 INTERVENTIONAL NCT00169585

Levofloxacin For The Management Of Patients With Abnormal Prostate Specific Antigen (PSA)

A National, Multicentric, Randomised, Controlled Trial. Applications of a Critical Pathway Using Levofloxacin for the Management of Patients With Abnormal PSA.

Sponsor: GlaxoSmithKline

Conditions Prostatic Hyperplasia Prostatitis

Interventions Levofloxacin oral tablets

Updated 6 times since 2017 Last updated: May 24, 2017 Started: Mar 31, 2005 Primary completion: Apr 30, 2007 Completion: Apr 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Prostatic Hyperplasia and Prostatitis, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 6 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Avellino, Italy , Bagno A Ripoli (FI), Italy , Bari, Italy , Bologna, Italy , Catania, Italy , Foggia, Italy , Lanzo Torinese (TO), Italy , Lecco, Italy , Matera, Italy , Messina, Italy and 6 more locations